Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Mirvetuximab soravtansine in folate receptor alpha (FR)high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
66 Targeting multiple peptide hormone receptors with the same drug entity appears to be the most promising strategy, where additive, or even synergistic, benefits of simultaneously activating two receptor signalling pathways in bone can be fully realised
Modest heart rate increases are generally well-tolerated, but contact your doctor if you experience symptomatic tachycardia, persistent palpitations, or resting heart rate consistently exceeding 100 beats per minute
Die Anwendung kann ber mehrere Wochen erfolgen, abhngig von den persnlichen Zielen
Expected appearance: Clear, colorless, particulate-free solution
US$ 26.39
US$ 25.65
US$ 29.70
US$ 23.10
